TrialTrials2017

The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan.

Tao Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.